To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

The Praxic Blade is Destiny 2’s lightsaber from Star Wars, and like all Exotic weapons, it has its own catalyst. Or catalysts ...

From GPT to Claude to Gemini, model names change fast, but use cases matter more. Here's how I choose the best model for the ...

Filmmaker Andy Muschietti swung and missed when he left horror behind for superheroes. Find out where to stream his ...

In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Yet too many CEOs still believe they can solve the problem by outbidding competitors for scarce talent. They can’t. The AI skills gap isn’t a hiring problem. It’s a systems problem.

Artificial intelligence is reshaping how humans see themselves, raising urgent ethical questions about autonomy, agency, and the construction of digital identities. A new study by Bogdan-Andrei Lungu ...

Imagine this: a hospital conference room, lights low, filled with decision-makers. A sales representative clicks through slides driven by Palantir Technologies’ (NASDAQ:PLTR) Foundry platform, ...

Palantir's stock is up nearly 10 % month-to-date and has gone even higher year-to-date, as bullish sentiment surges ahead of its second quarter earnings. Tempus AI shares, currently at about $64, have ...